SeraCare Life Sciences, Inc. Conference Call to Discuss Acquisition of Two Divisions of Boston Biomedica - Final.

Original Source: FD (FAIR DISCLOSURE) WIRE

OPERATOR: Ladies and gentlemen, thank you for standing by. Welcome to the SeraCare Life Sciences' conference call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. (OPERATOR INSTRUCTIONS). As a reminder, this conference is being recorded today Monday, April 19, 2004. I would now like to turn the conference over to Mr. Michael Crowley, President and Chief Executive Officer. Please go ahead, sir.

MICHAEL CROWLEY, PRESIDENT & CEO, SERACARE LIFE SCIENCES, INC.: Thank you. Good morning, everyone, and thank you for joining us today for the SeraCare Life Sciences' conference call to review the BBI acquisition that we announced Friday, the 16th of April. On the call today we have Barry Plost, Chairman of the SeraCare Life Sciences Board of Directors, myself, Michael Crowley, and Tim Hart, the CFO. Before we get started today, Sarah why don't you read us the Safe Harbor language.

SARAH NEUGEBAUER, SERACARE LIFE SCIENCES, INC.: Thank you Mike. SeraCare Life Sciences is a manufacturer and provider of biological materials and services essential to the manufacture of diagnostic tests, commercial bioproduction of therapeutic drugs and additional research applications. Certain statements that the company will make during this phone call and web cast are forward-looking statements that involve risks and uncertainties such as statements of the company's plans, goals, objectives, expectations, and intentions. Participants in this call are cautioned that while the forward-looking statements reflect the company's good faith beliefs, they are not guarantees of future performance and involve known and unknown risks and uncertainties and the company's actual results could differ materially from those discussed in this call.

The company assumes no obligation to publicly update or revise any forward-looking statement made during this call. Certain of these factors that could cause or contribute to such differences are described in Friday's news announcement and the company's filings with the Securities and Exchange Commission, including the company's Form 10-K, transition report on Form 10-K, quarterly reports on Form 10-Q and current report on Form 8-K. With that, I will turn the call over to Mike.

MICHAEL CROWLEY: Thank you Sarah. Barry, why don't you start us out today?

BARRY PLOST, CHAIRMAN, SERACARE LIFE SCIENCES, INC.: Thanks Mike. Friday was a very, very exciting day in the brief history of SeraCare Life Sciences and we certainly crossed a milestone in making acquisition of a company that was doing approximately $21 million to $22 million of revenue. As you know from the release, we acquired the Diagnostic and Biotech Divisions of BBI. But more than just the business we were fortunate enough to acquire a quality ISO 9001 manufacturer with a great productline and a workforce that is committed to quality manufacturing with an outstanding reputation. Certainly, …